Hoth Therapeutics Inc (NASDAQ:HOTH) Short Interest Update

Share on StockTwits

Hoth Therapeutics Inc (NASDAQ:HOTH) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 38,300 shares, a decrease of 11.3% from the December 15th total of 43,200 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 26,100 shares, the short-interest ratio is currently 1.5 days.

Separately, Benchmark initiated coverage on Hoth Therapeutics in a research note on Tuesday, October 15th. They issued a “speculative buy” rating and a $10.00 target price on the stock.

Shares of HOTH traded up $0.02 during mid-day trading on Tuesday, reaching $4.91. The company had a trading volume of 17,300 shares, compared to its average volume of 26,511. Hoth Therapeutics has a 52-week low of $3.26 and a 52-week high of $13.88. The stock has a market capitalization of $49.69 million and a P/E ratio of -9.82. The stock has a 50 day moving average of $5.13 and a two-hundred day moving average of $4.97.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). Analysts anticipate that Hoth Therapeutics will post -0.39 earnings per share for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.

Featured Article: How interest rates affect municipal bond prices

Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.